In This Article:
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual Meeting, being held April 25-30, 2025 in Chicago, Illinois.
Poster Presentation Details
Abstract 3136, “EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance”
-
Session: Experimental and Molecular Therapeutics - Therapeutic Approaches to Attack the Tumor Microenvironment
-
Date and Time: Monday, April 28, 2025, 2:30 PM - 5:00 P.M. CDT
-
Location: Poster Section 24
Abstract 5609, “A novel PTPN1/2 inhibitor with high oral bioavailability enhances the antitumoral response”
-
Session: Experimental and Molecular Therapeutics - Kinase and Phosphatase Inhibitors 3
-
Date and Time: Tuesday, April 29, 2025, 2:30 PM - 5:00 P.M. CDT
-
Location: Poster Section 20
iTeos’ exhibit booth at the AACR Annual Meeting is booth #3240.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
About EOS-215
EOS-215 is a potential best-in-class monoclonal antibody which blocks ligand binding to triggering receptor expressed on myeloid cells 2 (TREM2), switching off multiple tumor growth and survival promoting activities of tumor resident macrophages and effectively “reprogramming” the macrophages to allow for T cell activation. The therapeutic candidate has shown activity in both in vitro and in vivo highly immune resistant models and is currently in IND-enabling studies.
About PTPN1/2
iTeos has developed a novel small molecule inhibiting PTPN1/2. The PTPN1/2 phosphatases are negative regulators of cytokine signaling pathways and T cell receptor signaling. Inhibiting or depleting PTPN1/2 sensitizes cancer and immune cells to IFNγ, reshaping the tumor microenvironment and triggering a coordinated antitumor immune response.